SCHEMBL263670

SCHEMBL263670

CCOC(=O)c1cn(C2CCCC2)c2cc(F)ccc2c1=O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.47
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 2/20 0.43
HPGD P15428 4/20 0.42
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 3/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
PIM1 P11309 1/20 0.41
IRAK1 P51617 1/20 0.41
CAMK2B Q13554 1/20 0.41
CAMK2G Q13555 1/20 0.41
CAMK2D Q13557 1/20 0.41
PIM3 Q86V86 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9148070 0.96 ADRB2 (0.50) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL7129697 0.87 KDM4E (0.46) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL29766728 0.87 LMNA (0.50) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL7131487 0.86 LMNA (0.55) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL7129782 0.86 KDM4E (0.48) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL2080941 0.85 KMT2A (0.43) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL2080939 0.85 KMT2A (0.43) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL22506780 0.84 CNR2 (0.45) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL22506771 0.83 ADRB2 (0.41) ADRB2KDM4EKMT2AMEN1LMNA
SCHEMBL7123197 0.83 KDM4E (0.46) ADRB2KDM4EKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
EP-1995240-B1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-02-22 EP disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 ADRB2 149/4885KDM4E 3062/4885KMT2A 2966/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 ADRB2 178/4885KDM4E 3128/4885KMT2A 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.